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This editorial refers to ‘Percutaneous closure of patent foramen ovale in migraine with aura, a randomized 
controlled trial’, by H.P. Mattle et al., on page 2029. 
 
 
Mattle and co-workers present PRIMA, a randomized clinical trial comparing patent foramen ovale (PFO) 
closure using the Amplatzer occluder with medical management in patients suffering from migraine with aura 
(MA).1 The primary endpoint—the reduction in monthly migraine days between months 9 and 12 after 
randomization and 3 months before randomization—was not reached. Numerically, patients after PFO 
closure had a 1.2 day greater reduction in migraine days per month than controls, but this difference was not 
statistically significant. A secondary endpoint—response to therapy as defined by a reduction ≥50% of 
migraine days per month—was significant (38% of PFO closure patients vs. 15% of controls). Serious 
adverse events (SAE) occurred in 13% of closure patients and were procedure related in 11%; no SAE had 
lasting con- sequences. The PRIMA trial was terminated early due to slow enrolment. Of the 53 patients that 
were randomized to PFO closure, only 45 finally agreed to the procedure, the device was implanted in 41 
(77%), and successful closure was adjudicated at 6 months in 35 (66%). This may have obscured a 
possible benefit in the intention-to-treat analysis. On the other hand, interventions in migraine treatment carry 
a substantial placebo effect with respect to the reduction in migraine frequency.2 Intervention-related placebo 
effects were not controlled in PRIMA because medical treatment instead of a sham procedure was used as 
comparison. The placebo effect may have contributed to beneficial effects of PFO closure. Regardless of 
these limitations, the PRIMA results are consistent with those of the MIST trial which failed to demonstrate 
that PFO closure produced more frequent cessation of headache than a sham intervention.3  
Is PFO closure in MA patients now proven to be ineffective? This conclusion cannot be drawn from the trial 
data available to date. While these data preclude the use of PFO closure as a routine procedure outside of 
clinical trials, the scientific arguments for investigating the PFO closure approach to migraine prophylaxis 
remain valid and demand further research. One argument is the epidemiological link between MA and PFO 
which has been demonstrated in migrainers showing a higher frequency of PFOs, and vice versa.4 More 
importantly, microemboli that reach the brain through a right-to-left shunt may produce aura attacks by 
inducing cortical spreading depression (CSD).5 CSD consists of waves of neuronal and glial depolarization 
that propagate slowly across the cortex and are followed by hyper- and hypoperfusion. CSD is one 
mechanism proposed to cause migraine aura.6 CSDs also occur after stroke, subarachnoid haemorrhage, 
and brain injury.7 Microemboli may cause CSD in a brain that is susceptible. Genetically de- fined susceptibility 
is evident in CADASIL, the cerebral autosomal dominant angiopathy with subcortical infarcts and 
leukencephalopathy, where a mutation in the Notch-3 gene leads to dysfunctional vascular smooth muscle 
cells resulting in deficient autoregulation of cerebral arteries and arterioles.8 Endothelial dysfunction may be 
another reason for CSD susceptibility.5 Epidemiological links exist between migraine and conditions associated 
with endothelial cell dysfunction such as Raynaud’s phenomenon,9 Moyamoya disease,10 vascular 
retinopathy,11 and Sjogren’s syndrome.12 Von Willebrand factor level, a marker of endothelial cell 
dysfunction, is increased in13 and between migraine attacks.14 In addition, platelets may be dysfunctional in 
migraine patients.15 Taken together, these conditions predispose the MA patient to focal brain ischaemia 
which can trigger CSD and in turn cause aura and headaches (Figure 1). 
Based on the pathophysiology, it is plausible that an aura can be induced by a paradoxical embolus travelling 
through a PFO. This induction is a probabilistic event. Not every embolus will produce an attack nor will every 
attack be caused by an embolus in the patient with MA and a PFO because CSD can be triggered by a 
variety of events. The probabilistic link will decrease effect size and require larger sample sizes to prove the 
efficacy of PFO closure in MA. Considering additional uncertainty in clinical trials provided by patient-
related and methodological factors, as evident in the intention-to-treat analysis of PRIMA, a proof of efficacy 
will require careful patient selection. How to select patients is an open question. Taking the extreme view, PFO 
closure may only be a valuable treatment option for those who have a migraine attack triggered by a bubble 
test, i.e. the intravenous injection of agitated saline giving rise to air microemboli that travel through the PFO to 
produce transient brain ischaemia and CSD.16 Electroencephalography or functional magnetic resonance 
imaging could provide surrogate markers to identify clinically silent CSD and be used to widen patient 
selection. 
It seems reasonable to select patients with large PFOs and right-to-left shunt at rest who have a higher 
likelihood for microemboli. In light of PRIMA that was terminated due to slow recruitment, it seems unlikely that a 
future trial will be able to recruit a sufficiently large sample of selected patients. However, before giving up a 
potentially beneficial strategy to help migraine sufferers, cardiologists and neurologists need to join forces to 
obtain the scientific evidence that is currently lacking. 
 
References 
1. Mattle HP, Evers S, Hildick-Smith D, Becker WJ, Baumgartner H, Chataway J, Gawel M, Go¨bel H, 
Heinze A, Horlick E, Malik I, Ray S, Zermansky A, Findling O, Windecker S, Meier B. Percutaneous 
closure of patent foramen ovale in migraine with aura, a rando- mized controlled trial. Eur Heart J 
2016;37:2029–2036. 
2. Meissner K, Fa¨ssler M, Ru¨cker G, Kleijnen J, Hro´ bjartsson A, Schneider A, Antes G, Linde K. 
Differential effectiveness of placebo treatments: a systematic review of mi- graine prophylaxis. 
JAMA Intern Med 2013;173:1941 – 1951. 
3. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, Giovanni 
JV De, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A. Migraine 
Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, 
sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex 
septal repair im- plant to resolve refractory migraine headache. Circulation 2008;117:1397 – 1404. 
4. Schwedt TJ, Dodick DW. Patent foramen ovale and migraine—bringing closure to the subject. 
Headache 2006;46:663 – 671. 
5. Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and 
microembolisation. Lancet Neurol 2010;9:309 – 317. 
6. Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, 
Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by 
functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687 – 4692. 
7. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in 
neurological disease. Nat Med 2011;17:439 – 447. 
8. Pfefferkorn T, Stuckrad-Barre S von, Herzog J, Gasser T, Hamann GF, Dichgans M. Reduced 
cerebrovascular CO(2) reactivity in CADASIL: a transcranial Doppler sonography study. Stroke 
2001;32:17 – 21. 
9. O’Keeffe ST, Tsapatsaris NP, Beetham WP. Increased prevalence of migraine and chest pain in 
patients with primary Raynaud disease. Ann Intern Med 1992;116: 985 – 989. 
10. Park-Matsumoto YC, Tazawa T, Shimizu J. Migraine with aura-like headache asso- ciated with 
moyamoya disease. Acta Neurol Scand 1999;100:119 – 121. 
11. Rose KM, Wong TY, Carson AP, Couper DJ, Klein R, Sharrett AR. Migraine and ret- inal 
microvascular abnormalities: the Atherosclerosis Risk in Communities Study. Neurology 
2007;68:1694 – 1700. 
12. Pal B, Gibson C, Passmore J, Griffiths ID, Dick WC. A study of headaches and migraine in Sjo¨ 
gren’s syndrome and other rheumatic disorders. Ann Rheum Dis 1989;48:312 – 316. 
13. Cesar JM, Garc ı´a-Avello A, Vecino AM, Sastre JL, Alvarez-Cermen˜o JC. Increased levels of 
plasma von Willebrand factor in migraine crisis. Acta Neurol Scand 1995;91: 412 – 413. 
14. Tietjen GE, Al-Qasmi MM, Athanas K, Dafer RM, Khuder SA. Increased von Wille- brand factor in 
migraine. Neurology 2001;57:334 – 336. 
15. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HAM, van Vliet 
HHDM. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic 
and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a 
distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets 2006;17:528 – 
544. 
16. Dinia L, Roccatagliata L, Bonzano L, Finocchi C, Sette M Del. Diffusion MRI during migraine with 
aura attack associated with diagnostic microbubbles injection in subjects with large PFO. Headache 
2007;47:1455 – 1456. 
 
